Claim Missing Document
Check
Articles

Found 2 Documents
Search

17-2 Variasi Penggunaan Beeswax Lip Balm Stik dari Ekstrak Kulit Nanas (Ananas comosus (L.) Merr.) Najmi Hilaliyati; Resi Rizki Banjarani; Muhammad Arif; Nursyafni; Widiya Ismail
JFIOnline | Print ISSN 1412-1107 | e-ISSN 2355-696X Vol 17 No 2 (2025): Jurnal Farmasi Indonesia
Publisher : Pengurus Pusat Ikatan Apoteker Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35617/jfionline.v17i2.872

Abstract

Lip balm is a preparation applied to the lips to prevent dryness and chapping. Choosing the right lip balm base will significantly impact its quality and public acceptability. Beeswax has good binding properties, which help to produce a homogeneous mass. In this study, the active ingredient used was pineapple peel because it contains bromelain, which moisturizes the lips. The objectives of this study were to determine the appropriate formulation for lip balm preparations with pineapple peel extract (Ananas comosus (L.) Merr.) as the active ingredient and to determine the effect of varying beeswax base concentrations on the physical stability of lip balm preparations. The method used in this study was an experimental method to see which formulation was suitable. The study obtained a good formula with physical characteristics in accordance with SNI 16-4769-1998, including stability observation, pH measurement, homogeneity testing, irritation testing, moisture testing, and cycling test. The appropriate formula was found in formula 1 with a beeswax concentration of 1%, which produced a good color texture, aroma, adhesive power, and spreadability, a pH level suitable for the lips, no irritation, homogeneity, and stability during storage, resulting in a semi-solid and very smooth lip balm texture when used
Drug-Related Problems in Patients with Liver Failure: An Analysis of Pharmacokinetic Interactions and Dosing Inappropriateness A Literature Review Nasution, Izza Aulia Rizqika; Reza Laila Najmi; Resi Rizki Banjarani; Sari Rahmadhani; Restu Anisa Puteri
The Journal Of Pharmacy Vol. 3 No. 2 (2026): Journal Of Pharmacy UMRI
Publisher : LPPM, Universitas Muhammadiyah Riau

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Drug-related problems represent a major challenge in the pharmacotherapeutic management of patients with liver failure due to significant pharmacokinetic alterations, polypharmacy, and inappropriate dosing. Hepatic dysfunction affects drug absorption, distribution, metabolism, and elimination, thereby increasing the risk of adverse drug reactions, clinically significant drug–drug interactions, and therapeutic failure. This review aimed to summarize current evidence on the determinants of DRPs in patients with liver failure, focusing on pharmacokinetic changes, dose individualization, polypharmacy, and medication safety. A comprehensive literature review was conducted using PubMed, Embase, and the Cochrane Library to identify peer-reviewed studies published between 2015-2026. Keywords included liver failure, liver cirrhosis, drug-related problems, pharmacokinetics, dose adjustment, polypharmacy, and hepatic impairment. Eligible studies evaluated pharmacokinetic alterations, prescribing practices, medication safety, or clinical outcomes in adults with chronic liver disease. The findings consistently showed a high prevalence of DRPs in this population. Approximately one-quarter of commonly used medications required dose adjustment due to altered systemic exposure, while polypharmacy affected nearly one-third of patients and exceeded 50% in several cohorts. Inappropriate prescribing, inadequate dose individualization, and limited use of pharmacokinetic modeling were identified as major contributors to adverse drug reactions, hepatotoxicity, and clinically relevant drug–drug interactions. Additionally, reliance on conventional liver disease classification systems without integrating dynamic hepatic function markers often resulted in suboptimal therapy. Overall, pharmacokinetic alterations, polypharmacy, and inappropriate prescribing are key determinants of DRPs in patients with liver failure, underscoring the importance of individualized dosing, comprehensive medication review, pharmacokinetic modeling, and multidisciplinary pharmaceutical care to improve medication safety.